Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
SEATTLE, Nov. 23, 2016 -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it will present at the 28th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at 1:00 pm EST at the Lotte New York Palace Hotel.
A live audio webcast of the presentation can be accessed at www.aptevotherapeutics.com under the ‘Investors’ section of the website, under ‘Events.’ An audio reply of the webcast will be available following the live webcast.
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Our core technology is the ADAPTIR™ (modular protein technology) platform. Aptevo has four commercial products in the areas of hematology and infectious diseases, as well as various investigational stage product candidates in immuno-oncology.
Source:
Aptevo Therapeutics
Stacey Jurchison
Senior Director, Investor Relations and Corporate Communications
206-859-6628
[email protected]
